NasdaqGM - Nasdaq Real Time Price USD

TScan Therapeutics, Inc. (TCRX)

7.26

+0.14

(+1.97%)

At close: 4:00 PM EDT

7.44

+0.18

(+2.52%)

After hours: 4:46 PM EDT

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

WALTHAM, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of one abstract for oral presentation and four abstracts for poster presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11 in Baltimore, MD

GlobeNewswire yesterday

TCRX
+1.97%
TScan Therapeutics Announces Closing of Upsized Public Offering

WALTHAM, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the closing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of $7.1300 per share, which was equal to the closing price of its voting common stock on the Nasd

GlobeNewswire 4 days ago

TCRX
+1.97%
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of the market price of $7.1300 per share, which was equal to the closing price of its voting comm

GlobeNewswire 6 days ago

TCRX
+1.97%
TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

WALTHAM, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has commenced an underwritten public offering of $125 million of shares of its voting common stock and, in lieu of voting common stock, to certain investors that so choose, pre-funded warrants to purchase share

GlobeNewswire 7 days ago

TCRX
+1.97%
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Over 40 solid tumor patients have completed all biomarker testing in the screening protocol; ~60% of these patients qualify for at least one TCR-T in the ImmunoBank and ~30% are eligible for multiplex therapy Patients identified across all six TCR-T cohorts in solid tumor program with dosing of first three expected in early May All eight patients in the heme program treated with TSC-100 or TSC-101 remain relapse-free with no detectable cancer to date; median follow-up of >10 months WALTHAM, Mass

GlobeNewswire 7 days ago

TCRX
+1.97%
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial developmentWALTHAM, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer. Dr. Louis has extens

GlobeNewswire 15 days ago

TCRX
+1.97%
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024 at 2:15 p.m. Eastern Time. A webcast of the presentation will be available on the “Events and Presentatio

GlobeNewswire 21 days ago

TCRX
+1.97%
Hedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16%

Key Insights Significantly high institutional ownership implies TScan Therapeutics' stock price is sensitive to their...

Simply Wall St. 28 days ago

TCRX
+1.97%
Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With

Generally speaking, you want to minimize your exposure to cheap stocks under $10. Yes, smaller companies have the potential to rise dramatically higher than their larger counterparts. In part, that’s because they’re unpredictable – and this ambiguity cuts both ways. Sure, cheap stocks under $10 have the benefit of the law of small numbers working in their favor during upswings. Basically, it doesn’t take as much energy to push a pebble up the mountain. However, if you climb too high up that moun

InvestorPlace last month

TAC

TCRX
+1.97%
CPG
TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline

Fourth Quarter and Full Year 2023 Financial Results and Business Developments

GuruFocus.com last month

TCRX
+1.97%
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates

TScan Therapeutics, Inc. (TCRX) delivered earnings and revenue surprises of 30% and 145.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

TCRX
+1.97%
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Presented updated data from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies at the Tandem Meetings of ASTCT and CIBMTR; 8/8 (100%) patients in treatment arms are relapse-free and show complete donor chimerism Announced the clearance of two additional INDs for Solid Tumor Program: TSC-201-B0702 targeting MAGE-C2 on HLA-B*07:02 and TSC-204-A0101 targeting MAGE-A1 on HLA-A*01:01 Solid tumor clinical trial actively enrolling, with initial data for singleplex and m

GlobeNewswire last month

TCRX
+1.97%
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

WALTHAM, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will participate in the Cell Therapy Corporate Panel Discussion at the TD Cowen 44th Annual Health Care Conference being held at the Marriott Copley Place in Boston on Wednesday, March 6, 2024 at 9:10 a

GlobeNewswire last month

TCRX
+1.97%
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

All eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101 Patient with high-risk, TP53-mutated MDS is relapse-free for over one year following treatment with TSC-101 Patient with AML converted from detectable to undetectable disease following treatment with TSC-101 Data presented at TANDEM meeting suggests complete donor chimerism is an early indicator of treatment success Company to host virtual

GlobeNewswire last month

TCRX
+1.97%
TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?

TScan Therapeutics, Inc. (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 2 months ago

TCRX
+1.97%
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

TScan’s abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of initial data from a large prospective clinical trial assessing the relationship between donor chimerism and risk of relapse WALTHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of p

GlobeNewswire 2 months ago

TCRX
+1.97%
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

WALTHAM, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development. Dr. Pinchasik brings to TScan over a decade of experience in clinical development across the pharmaceutical and biotechnology indus

GlobeNewswire 2 months ago

TCRX
+1.97%
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appointment of Jason A. Amello as Chief Financial Officer. Mr. Amello, a senior finance executive, brings to TScan nearly three decades of expertise in financial strategy, business development, and operations in the

GlobeNewswire 2 months ago

TCRX
+1.97%
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Presentation to include additional results from ongoing Phase 1 study of TSC-100 and TSC-101 for the treatment of heme malignancies WALTHAM, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the acceptance of an abstract for oral presentation at the Best Abstracts session of th

GlobeNewswire 3 months ago

TCRX
+1.97%
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Reported positive initial data from Phase 1 heme program at the 65th American Society of Hematology (ASH) Annual Meeting Clearance of INDs for four TCR-Ts, including a TCR-T for PRAME, in support of use of multiple TCRs in combination for the solid tumor clinical trial Entered a collaboration with Amgen to identify novel targets in Crohn’s Disease Closed underwritten public offering with net proceeds of $140.6 million, funding operations into 2026 WALTHAM, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -

GlobeNewswire 3 months ago

TCRX
+1.97%

Performance Overview

Return	TCRX	S&P 500
YTD	+24.53%	+6.30%
1-Year	+193.93%	+22.67%
3-Year	--	+17.18%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TScan Therapeutics, Inc. (TCRX)

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

TScan Therapeutics Announces Closing of Upsized Public Offering

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Hedge funds investors control 50% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 16%

Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With

TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Performance Overview